Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Pharmacokinetic Study of VCT220 in Subjects With Varying Degrees of Hepatic Impairment and Normal Hepatic Function

NCT06938529 is registered in ClinicalTrials.gov with Vincentage Pharma Co., Ltd as lead sponsor.

NCT NCT06938529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06938529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Pharmacokinetic Study of VCT220 in Subjects With Varying Degrees of Hepatic Impairment and Normal Hepatic Function
Lead sponsor
Vincentage Pharma Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
April 18, 2025
Completion date
July 25, 2025
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight